Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 40771 

Dated: August 23, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–18161 Filed 8–25–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–N–4561] 

Bone, Reproductive and Urologic 

Drugs Advisory Committee; Notice of 

Meeting; Establishment of a Public 

Docket; Request for Comments 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice; establishment of a 

public docket; request for comments. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) 

announces a forthcoming public 

advisory committee meeting of the 

Bone, Reproductive and Urologic Drugs 

Advisory Committee. The general 

function of the committee is to provide 

advice and recommendations to the 

Agency on FDA’s regulatory issues. The 

meeting will be open to the public. FDA 

is establishing a docket for public 

comment on this document. 

DATES: The public meeting will be held 

on December 7, 2017, from 8 a.m. to 5 

p.m. 

ADDRESSES: FDA White Oak Campus, 

10903 New Hampshire Ave., Bldg. 31 

Conference Center, the Great Room (Rm. 

1503), Silver Spring, MD 20993–0002. 

Answers to commonly asked questions 

including information regarding special 

accommodations due to a disability, 

visitor parking, and transportation may 

be accessed at: https://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm408555.htm. 

FDA is establishing a docket for 

public comment on this meeting. The 

docket number is FDA–2017–N–4561. 

The docket will close on December 6, 

2017. Submit either electronic or 

written comments on this public 

meeting by December 6, 2017. Please 

note that late, untimely filed comments 

will not be considered. Electronic 

comments must be submitted on or 

before December 6, 2017. The https://

www.regulations.gov electronic filing 

system will accept comments until 

midnight Eastern Time at the end of 

December 6, 2017. Comments received 

by mail/hand delivery/courier (for 

written/paper submissions) will be 

considered timely if they are 

postmarked or the delivery service 

acceptance receipt is on or before that 

date. 

Comments received on or before 

November 22, 2017, will be provided to 

the committee. Comments received after 

that date will be taken into 

consideration by the Agency. 

You may submit comments as 

follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

2017–N–4561 for ‘‘Bone, Reproductive 

and Urologic Drugs Advisory 

Committee; Notice of Meeting; 

Establishment of a Public Docket; 

Request for Comments.’’ Received 

comments, those filed in a timely 

manner (see ADDRESSES), will be placed 

in the docket and, except for those 

submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://www.gpo.gov/ 

fdsys/pkg/FR-2015-09-18/pdf/2015- 

23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852. 

FOR FURTHER INFORMATION CONTACT: 

Kalyani Bhatt, Center for Drug 

Evaluation and Research, Food and 

Drug Administration, 10903 New 

Hampshire Ave., Bldg. 31, Rm. 2417, 

Silver Spring, MD 20993–0002, 301– 

796–9001, Fax: 301–847–8533, 

kalyani.bhatt@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area). A notice in the 

Federal Register about last minute 

modifications that impact a previously 

announced advisory committee meeting 

cannot always be published quickly 

enough to provide timely notice. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES
40772 Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 

Therefore, you should always check the 

Agency’s Web site at https://

www.fda.gov/AdvisoryCommittees/ 

default.htm and scroll down to the 

appropriate advisory committee meeting 

link, or call the advisory committee 

information line to learn about possible 

modifications before coming to the 

meeting. 

SUPPLEMENTARY INFORMATION: 

Agenda: The committee will discuss 

appropriate patient selection criteria 

and clinical trial design features, 

including acceptable endpoints, for 

demonstrating clinical benefit for drugs 

intended to treat interstitial cystitis and 

bladder pain syndrome. The committee 

will also discuss whether bladder pain 

syndrome and interstitial cystitis reflect 

overlapping or different populations, 

and whether it is appropriate to assess 

efficacy in the same way for both 

conditions. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at https://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee meeting 

link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. All electronic and 

written submissions submitted to the 

docket (see ADDRESSES) on or before 

November 22, 2017, will be provided to 

the committee. Oral presentations from 

the public will be scheduled between 

approximately 1 p.m. and 2 p.m. Those 

individuals interested in making formal 

oral presentations should notify the 

contact person and submit a brief 

statement of the general nature of the 

evidence or arguments they wish to 

present, the names and addresses of 

proposed participants, and an 

indication of the approximate time 

requested to make their presentation on 

or before November 14, 2017. Time 

allotted for each presentation may be 

limited. If the number of registrants 

requesting to speak is greater than can 

be reasonably accommodated during the 

scheduled open public hearing session, 

FDA may conduct a lottery to determine 

the speakers for the scheduled open 

public hearing session. The contact 

person will notify interested persons 

regarding their request to speak by 

November 15, 2017. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

Agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with disabilities. 

If you require special accommodations 

due to a disability, please contact 

Kalyani Bhatt at least 7 days in advance 

of the meeting. 

FDA is committed to the orderly 

conduct of its advisory committee 

meetings. Please visit our Web site at 

https://www.fda.gov/ 

AdvisoryCommittees/ 

AboutAdvisoryCommittees/ 

ucm111462.htm for procedures on 

public conduct during advisory 

committee meetings. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: August 22, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–18131 Filed 8–25–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the National Advisory 

Committee on Rural Health and Human 

Services 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice of Meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, notice 

is hereby given of a National Advisory 

Committee on Rural Health and Human 

Services (NACRHHS) meeting. The 

meeting will be open to the public. 

Informaton about the NACRHHS 

meeting can be obtained by accessing 

the following Web site: http://

www.hrsa.gov/advisorycommittees/ 

rural/. 

DATES: The meeting will be held on 

September 11, 2017, 8:45 a.m. to 5:00 

p.m. MDT; September 12, 2017, 8:30 

a.m. to 5:15 p.m. MDT; and September 

13, 2017, 8:30 a.m. to 11:00 a.m. MDT. 

ADDRESSES: This meeting will be held at 

the Spring Hill Suites located at 424 E. 

Parkcenter Blvd., Boise, Idaho 83706, 

(208) 342–1044. 

FOR FURTHER INFORMATION CONTACT: 

Steve Hirsch, MSLS, Administrative 

Coordinator, National Advisory 

Committee on Rural Health and Human 

Services, Health Resources and Services 

Administration, Parklawn Building, 

17W29C, 5600 Fishers Lane, Rockville, 

MD 20857, Telephone (301) 443–0835, 

Fax (301) 443–2803. 

SUPPLEMENTARY INFORMATION: 

NACRHHS provides counsel and 

recommendations to the Secretary with 

respect to the delivery, research, 

development, and administration of 

health and human services in rural 

areas. 

The meeting on Monday, September 

11, will be called to order at 8:45 a.m. 

by the Chairperson of the Committee, 

The Honorable Ronnie Musgrove. The 

Committee will examine the issue of 

suicide in rural areas and the issue of 

Rural Health Clinic Modernization. The 

day will conclude with a period of 

public comment at approximately 5:15 

p.m. 

The Committee will break into 

Subcommittees and depart for site visits 

Tuesday morning, September 12, at 

approximately 8:15 a.m. Subcommittees 

will visit First Baptist Church, 126 S. 

Hayes Avenue in Emmett, Idaho and the 

North Canyon Medical Center, 267 N. 

Canyon Drive in Gooding, Idaho. The 

day will conclude at the Spring Hill 

Suites with a period of public comment 

at approximately 5:00 p.m. 

The Committee will meet to 

summarize key findings and develop a 

work plan for the next quarter and the 

following meeting on Wednesday 

morning, September 13, at 8:30 a.m. 

Persons interested in attending any 

portion of the meeting should contact 

Alfred Delena at the Federal Office of 

Rural Health Policy (FORHP) via 

telephone at (301) 443–3388 or by email 

at ADelena@hrsa.gov. The Committee 

meeting agenda will be posted on the 

Committee’s Web site at http://

www.hrsa.gov/advisorycommittees/ 

rural/. 

Amy McNulty, 

Acting Director, Division of the Executive 

Secretariat. 

[FR Doc. 2017–18139 Filed 8–25–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Notice of Intent To Establish the Pain 

Management Best Practices InterAgency Task Force and Request for 

Nominations for Task Force Members 

AGENCY: Office of the Assistant 

Secretary for Health, Office of the 


asabaliauskas on DSKBBXCHB2PROD with NOTICES